Lv1
30 积分 2024-02-28 加入
Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
1个月前
已完结
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
1个月前
已完结
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy for first-line ICI-combined regimen
1个月前
已完结
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
3个月前
已完结
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
3个月前
已完结
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
3个月前
已完结
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
3个月前
已完结
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
3个月前
已完结
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer
5个月前
已完结
皖公网安备34019202002308
